Publication date: September 2026 Source: Current Radiopharmaceuticals, Volume 19, Issue 5 Author(s): Danhong Chen, Xiaoli Huang, Chongmei Huang, Yan Wang
Research progress on multimodal monitoring combined with biomarkers in critical care management strategies after neurointerventional surgery. // Current Radiopharmaceuticals. – URL: https://www.sciencedirect.com/science/article/pii/S1874471026000824?dgcid=rss_sd_all
Research progress on multimodal monitoring combined with biomarkers in critical care management strategies after neurointerventional surgery. Current Radiopharmaceuticals. https://www.sciencedirect.com/science/article/pii/S1874471026000824?dgcid=rss_sd_all
“Research progress on multimodal monitoring combined with biomarkers in critical care management strategies after neurointerventional surgery.” Current Radiopharmaceuticals.
@article{article42747,
title = {Research progress on multimodal monitoring combined with biomarkers in critical care management strategies after neurointerventional surgery},
journal = {Current Radiopharmaceuticals},
url = {https://www.sciencedirect.com/science/article/pii/S1874471026000824?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...